REFERENCES
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998, 352, 930–942.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365, 1687–1717.
- Herold, C.I.; Djulbegovic, B.; Hozo, I.; Lyman, G.H. Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Res Treat. 2009. Oct 6 [Epub ahead of print].
- Jones, L.W.; Haykowsky, M.; Peddle, C.J.; Joy, A.A.; Pituskin, E.N.; Tkachuk, L.M.; Courneya, K.S.; Slamon, D.J.; Mackey, J.R. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Oncologist 2007, 12, 1156–1164.
- Jones, S.; Holmes, F.A.; O’Shaughnessy, J.; Blum, J.L.; Vukelja, S.J.; Mclntyre, K.J.; Pippen, J.E; Bordelon, J.H; Kirby, R.L.; Sandbach, J.; Hyman, W.J.; Richards, D.A.; Mennel, R.G.; Boehm, K.A.; Meyer, W.G.; Asmar, L.; Mackey, D.; Riedel, S.; Muss, H.; Savin, M.A. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology pesearch trial 9735. J Clin Oncol. 2009, 27, 1177–1183.
- Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Rolski, J.; Chan, A.; Mackey, J.; Liu, M.; Pinter, T.; Valero, V.; Falkson, C.; Fornander, T.; Shiftan, T.; Olsen, S.; Buyse, M.; Kiskartalyi, T.; Landreau, V.; Wilson, V.; Press, M.; Crown, J. on Behalf of BC1RG006 Investigators. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study, San Antonio Breast Cancer Symposium. San Antonio, TX,2009.